Abstract
Triiodobenzoic acid (TIBA) represents the core structure of most clinically used contrast agents for computed tomography and other X-ray procedures. To construct an intracellular radiopaque contrast agent, TIBA was coupled to various different positively and negatively charged fluorescein iothiocyanate (FITC)-labelled peptides. TIBA coupled to the SV40 T Antigen nuclear localization sequence (NLS) stained 80% of human glioma cells and caused cell death. This occurred with C- or N-terminal binding of TIBA and with the correct or mutant NLS. No cell death and only small numbers of stained cells (below 3 %) were observed after incubation with NLS conjugates lacking TIBA or after incubation with TIBA-conjugates containing a negatively charged polyglutamic acid stretch. TIBA-conjugates containing the Antennapedia-derived cell-penetrating peptide penetratin were only nuclearly taken up when TIBA and FITC were coupled to lysines outside the 16-amino acid peptide sequence. The study shows that intracellular TIBA may have potential as a chemotherapeutic agent rather than a contrast agent.
Keywords: 2,3,5-triiodobenzoic acid, NLS, cell nucleus, FITC, transmembrane transport, glioma, penetratin, polyglutamic acid
Medicinal Chemistry
Title: Cell Nucleus Directed 2,3,5-triiodobenzoic Acid Conjugates
Volume: 5 Issue: 4
Author(s): Alexander Sturzu, Ulrich Vogel, Alireza Gharabaghi, Alexander Beck, Hubert Kalbacher, Hartmut Echner and Stefan Heckl
Affiliation:
Keywords: 2,3,5-triiodobenzoic acid, NLS, cell nucleus, FITC, transmembrane transport, glioma, penetratin, polyglutamic acid
Abstract: Triiodobenzoic acid (TIBA) represents the core structure of most clinically used contrast agents for computed tomography and other X-ray procedures. To construct an intracellular radiopaque contrast agent, TIBA was coupled to various different positively and negatively charged fluorescein iothiocyanate (FITC)-labelled peptides. TIBA coupled to the SV40 T Antigen nuclear localization sequence (NLS) stained 80% of human glioma cells and caused cell death. This occurred with C- or N-terminal binding of TIBA and with the correct or mutant NLS. No cell death and only small numbers of stained cells (below 3 %) were observed after incubation with NLS conjugates lacking TIBA or after incubation with TIBA-conjugates containing a negatively charged polyglutamic acid stretch. TIBA-conjugates containing the Antennapedia-derived cell-penetrating peptide penetratin were only nuclearly taken up when TIBA and FITC were coupled to lysines outside the 16-amino acid peptide sequence. The study shows that intracellular TIBA may have potential as a chemotherapeutic agent rather than a contrast agent.
Export Options
About this article
Cite this article as:
Sturzu Alexander, Vogel Ulrich, Gharabaghi Alireza, Beck Alexander, Kalbacher Hubert, Echner Hartmut and Heckl Stefan, Cell Nucleus Directed 2,3,5-triiodobenzoic Acid Conjugates, Medicinal Chemistry 2009; 5 (4) . https://dx.doi.org/10.2174/157340609788681485
DOI https://dx.doi.org/10.2174/157340609788681485 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry The Anti-Tumor Effect and Mechanisms of Action of Penta-Acetyl Geniposide
Current Cancer Drug Targets Bone Regeneration and Repair
Current Stem Cell Research & Therapy MicroRNAs as Cancer Biomarkers
MicroRNA Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells
Current Radiopharmaceuticals Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Modern Treatments for Gliomas Improve Outcome
Current Cancer Therapy Reviews Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets